A meta-analysis of 1,478 RAS wild-type mCRC patients found PIK3CA mutations were associated with significantly worse PFS (HR 1.38) and OS (HR 1.58), while BRAF mutations were associated with worse PFS (HR 1.68) and OS (HR 1.27). (J Vis Exp)
PIK3CA and BRAF mutations linked to worse outcomes in RAS wild-type mCRC on anti-EGFR therapy
The CRC Digest